Related Experiment Video
Updated: May 22, 2026
09:57
Separation of Bioactive Small Molecules, Peptides from Natural Sources and Proteins from Microbes by Preparative Isoelectric Focusing (IEF) Method
Published on: June 14, 2020
Hypoglycamic activity of extracts fo ficus glomerata
K Balaji1, V Venkiteshwarlu, V M Reddy
1University College of Pharmaceutical Sciences, Kakatiya University, Warangal- 506 009, Andhra Pradesh.
Ancient Science of Life
|May 5, 2012
Summary
Ficus glomerata leaf and root bark extracts were tested for their ability to lower blood sugar. Chloroform and methanolic leaf extracts, along with chloroform root bark extract, showed significant hypoglycemic effects in rabbits.
Area of Science:
- Pharmacology
- Ethnobotany
- Phytochemistry
Background:
- Ficus glomerata, a plant used in traditional medicine, has potential therapeutic properties.
- Understanding the phytochemical constituents and pharmacological activities of Ficus glomerata is crucial for its medicinal applications.
Purpose of the Study:
- To investigate the hypoglycemic activity of various Ficus glomerata extracts.
- To identify potential bioactive compounds responsible for the observed effects.
Main Methods:
- Successive solvent extraction was used to obtain petroleum ether, chloroform, methanol, and aqueous extracts from Ficus glomerata leaves and root bark.
- Qualitative phytochemical analysis was performed on all extracts.
- Hypoglycemic activity was assessed in normal and glucose-fed fasted rabbits.
Main Results:
- Phytochemical screening revealed the presence of various secondary metabolites in the different extracts.
- Chloroform and methanolic leaf extracts, as well as the chloroform root bark extract, demonstrated significant hypoglycemic activity.
- These active extracts effectively reduced blood glucose levels in tested rabbits.
Conclusions:
- Ficus glomerata possesses significant hypoglycemic properties, particularly in its leaf and root bark extracts.
- The study validates the traditional use of Ficus glomerata for managing blood sugar levels.
- Further research is warranted to isolate and characterize the specific compounds responsible for the hypoglycemic activity.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...